In-vitro antiplatelet effect of melatonin in healthy individuals and patients with type 2 diabetes mellitus.

Allan BöhmV LaukoK DostalovaI BalanovaI VargaB BezakN JajcayR MoravcikL LazurovaP SlezakV MojtoM KollarovaK PetrikovaK DanovaM Zeman

Published in: Journal of endocrinological investigation (2023)

Platelet aggregation was inhibited by melatonin in healthy individuals. In-vitro antiplatelet effect of melatonin in type 2 DM patients is significantly attenuated.

Keyphrases

end stage renal disease
newly diagnosed
prognostic factors
glycemic control
patient reported outcomes
adipose tissue
metabolic syndrome